<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Gen-Probe Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/gen-probe-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AKRX) Company News for June 07, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/07/akrx-company-news-for-june-07-2011-corporate-summary/75683</link>
		<comments>http://www.stockbloghub.com/2011/06/07/akrx-company-news-for-june-07-2011-corporate-summary/75683#comments</comments>
		<pubDate>Tue, 07 Jun 2011 16:57:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Akorn Inc]]></category>
		<category><![CDATA[AKRX]]></category>
		<category><![CDATA[AMED]]></category>
		<category><![CDATA[Amedisys Inc.]]></category>
		<category><![CDATA[BAP]]></category>
		<category><![CDATA[Coventry Health Care Inc.]]></category>
		<category><![CDATA[Credicorp Limited]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[CVH]]></category>
		<category><![CDATA[EXEL]]></category>
		<category><![CDATA[Exelixis Inc]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Lloyds Banking Group plc]]></category>
		<category><![CDATA[LOW]]></category>
		<category><![CDATA[Lowe's Companies Inc.]]></category>
		<category><![CDATA[LYG]]></category>
		<category><![CDATA[Merge Healthcare Incorporated.]]></category>
		<category><![CDATA[MRGE]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75683</guid>
		<description><![CDATA[•    Share prices of home nursing provider Amedisys, Inc.(NASDAQ:AMED) fell 7.41% after CRT Capital reduced its earnings estimates for fiscal 2011 •    According to Canaccord Genuity, data from a trial of Exelixis, Inc&#8217;s (NASDAQ:EXEL) cancer-drug candidate could possibly worsen its regulatory strategy •    According to the Wall Street Journal, Novartis AG (NYSE:NVS) could possibly opt out from the buying race for medical test manufacturer Gen-Probe Inc (NASDAQ:GPRO) •    Merge Healthcare Inc (NASDAQ:MRGE) announced plans to buy Ophthalmic Imaging Systems (OTC:OISI) for a deal worth $30.3 million in stock •    U.S.-listed shares of Peruvian metal producer Southern Copper Corp. (NYSE:SCCO) declined 11.35%, after a former army rebel won Peru&#8217;s presidential elections •    Raymond James Financial Inc. downgraded Credicorp Ltd (NYSE:BAP) , the Peruvian financial-services firm from &#8220;Outperform&#8221; to &#8220;Underperform&#8221; rating •    ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/07/akrx-company-news-for-june-07-2011-corporate-summary/75683/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AWK) Company News for May 27, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/27/awk-company-news-for-may-27-2011-corporate-summary/75079</link>
		<comments>http://www.stockbloghub.com/2011/05/27/awk-company-news-for-may-27-2011-corporate-summary/75079#comments</comments>
		<pubDate>Fri, 27 May 2011 17:03:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Utilities]]></category>
		<category><![CDATA[Water Utilities]]></category>
		<category><![CDATA[American Water Works Company Inc]]></category>
		<category><![CDATA[AWK]]></category>
		<category><![CDATA[BIG]]></category>
		<category><![CDATA[Big Lots Inc.]]></category>
		<category><![CDATA[Diamond Foods Inc.]]></category>
		<category><![CDATA[DMND]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[HJ Heinz Company]]></category>
		<category><![CDATA[HNZ]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[RadioShack Corporation]]></category>
		<category><![CDATA[RSH]]></category>
		<category><![CDATA[TD]]></category>
		<category><![CDATA[TIF]]></category>
		<category><![CDATA[Tiffany & Company]]></category>
		<category><![CDATA[Toronto-Dominion Bank]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75079</guid>
		<description><![CDATA[•    Big Lots, Inc. (NYSE:BIG) reported Q1 EPS of $0.70, above the Zacks Consensus Estimates of $0.68 per share. Revenues for the quarter fell 0.6% year-over-year to $1.23 billion, lower than the Zacks Consensus Estimate of $1.276 billion •    TD Bank Group (NYSE:TD) announced Q2 EPS of $1.62, lower than the Zacks Consensus Estimate of $1.66 per share. Revenues for the quarter grew 7.5% year-over-year to $5.23 billion, falling short of the Zacks Consensus Estimate of $5.355 billion •    Tiffany &#38; Co. (NYSE:TIF) posted Q1 EPS of $0.63, higher than the Zacks Consensus Estimate of $0.57. Revenues for the quarter grew 20% year-over-year to $761 million, beating the Zacks Consensus Estimate of $701 million •    H.J. Heinz Company (NYSE:HNZ) announced Q4 EPS of $0.69, lower than the Zacks Consensus Estimate ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/27/awk-company-news-for-may-27-2011-corporate-summary/75079/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GPRO) Gen-Probe Files Pre-market Approval Application for Prostate Cancer Test</title>
		<link>http://www.stockbloghub.com/2010/09/26/gpro-gen-probe-files-pre-market-approval-application-for-prostate-cancer-test/52758</link>
		<comments>http://www.stockbloghub.com/2010/09/26/gpro-gen-probe-files-pre-market-approval-application-for-prostate-cancer-test/52758#comments</comments>
		<pubDate>Mon, 27 Sep 2010 05:04:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[NAT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52758</guid>
		<description><![CDATA[Diagnostic products maker Gen-Probe Inc. (GPRO) has submitted a Pre-market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its PROGENSA PCA3 assay, a novel molecular test designed to aid the diagnosis of prostate cancer. Gen-Probe is seeking FDA approval to use the assay to test urine specimens from men who earlier had a negative prostate biopsy. This represents the second of the four PMA submissions that Gen-Probe plans to complete in 2010. The FDA has formally accepted the PROGENSA PMA and has advised Gen-Probe that a meeting (timeline unspecified) of the Medical Devices Advisory Committee&#8217;s Immunology Panel will be necessary to support approval of the filling. Gen-Probe acquired the exclusive global rights to the PCA3 (a genetic marker for prostate cancer) from Canadian cancer diagnostic tests ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/26/gpro-gen-probe-files-pre-market-approval-application-for-prostate-cancer-test/52758/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GPRO) Gen-Probe&#8217;s Earnings Report Leaps Ahead of Forecast</title>
		<link>http://www.stockbloghub.com/2010/07/31/gpro-gen-probes-earnings-report-leaps-ahead-of-forecast/45488</link>
		<comments>http://www.stockbloghub.com/2010/07/31/gpro-gen-probes-earnings-report-leaps-ahead-of-forecast/45488#comments</comments>
		<pubDate>Sat, 31 Jul 2010 16:17:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[NAT]]></category>
		<category><![CDATA[Nordic American Tanker Shipping Limited]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45488</guid>
		<description><![CDATA[Diagnostic product maker Gen-Probe Inc. (GPRO) announced second-quarter fiscal 2010 adjusted earnings of 52 cents per share, exceeding the Zacks Consensus Estimate of 49 cents and the year-ago earnings of 45 cents. Net income soared 42% year-over-year to $28.1 million (or 57 cents a share), riding on solid top-line growth. Revenues Revenues surged 15% year over year to $138.6 million, beating the Zacks Consensus Estimate of $137 million, buoyed by double-digit sales growth from the clinical diagnostics and blood screening product businesses. Clinical diagnostic revenues grew 10%, fueled by higher adoption of APTIMA Combo 2 assay and Prodesse products. Blood screening product sales cruised 22% year over year to $55.7 million. Growth was supported by higher shipment of Procleix Ultrio and West Nile virus assays, as well as favorable currency ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/31/gpro-gen-probes-earnings-report-leaps-ahead-of-forecast/45488/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GPRO) Gen-Probe Invests $50 Million in Pacific Biosciences</title>
		<link>http://www.stockbloghub.com/2010/07/05/gpro-gen-probe-invests-50-million-in-pacific-biosciences/40813</link>
		<comments>http://www.stockbloghub.com/2010/07/05/gpro-gen-probe-invests-50-million-in-pacific-biosciences/40813#comments</comments>
		<pubDate>Mon, 05 Jul 2010 16:14:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[NAT]]></category>
		<category><![CDATA[Nordic American Tanker Shipping Limited]]></category>
		<category><![CDATA[SMRT]]></category>
		<category><![CDATA[Stein Mart Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=40813</guid>
		<description><![CDATA[Diagnostic product maker Gen-Probe Inc (GPRO) has made a $50 million strategic investment in privately-held DNA sequencing firm Pacific Biosciences (PacBio). The companies will collaborate on developing products based on their proprietary technologies. Per the deal, the companies will combine their efforts to develop new clinical diagnostic systems, leveraging PacBio&#8217;s Single Molecule Real Time (SMRT) DNA sequencing technology platform and Gen-Probe&#8217;s diagnostic expertise. They will initially collaborate for up to 30 months with the goal of building a long-term relationship and improving diagnostic capabilities. Moreover, the companies will buy each other&#8217;s products on preferred terms of trade. California-based Gen-Probe has been a pioneer in the commercial and scientific development of nucleic acid testing (NAT) for the diagnosis of infectious diseases. The company sells its products in the clinical diagnostic as well ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/05/gpro-gen-probe-invests-50-million-in-pacific-biosciences/40813/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NEOG) Neogen&#8217;s Earnings Inches Past Estimates</title>
		<link>http://www.stockbloghub.com/2010/03/31/neog-neogens-earnings-inches-past-estimates/32390</link>
		<comments>http://www.stockbloghub.com/2010/03/31/neog-neogens-earnings-inches-past-estimates/32390#comments</comments>
		<pubDate>Wed, 31 Mar 2010 20:48:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[NEOG]]></category>
		<category><![CDATA[Neogen Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32390</guid>
		<description><![CDATA[Neogen Corp. (NEOG) posted fiscal 2010 third-quarter results on Monday. The company’s net income recorded a strong growth of 37.5% to $3.9 million, or 17 cents per share from $2.8 million, or 12 cents per share in the year-ago period. The result also squeezed past the Zacks Consensus Estimate of 16 cents and was primarily driven by robust sales of food safety test kits. Neogen develops and markets products dedicated to food and animal safety. The company&#8217;s Food Safety division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen&#8217;s Animal Safety division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides. The Lansing, MI-based Neogen witnessed a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/31/neog-neogens-earnings-inches-past-estimates/32390/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NEOG) Neogen Beats Earnings Expectations by a Penny</title>
		<link>http://www.stockbloghub.com/2009/12/22/neog-neogen-beats-earnings-expectations-by-a-penny/23448</link>
		<comments>http://www.stockbloghub.com/2009/12/22/neog-neogen-beats-earnings-expectations-by-a-penny/23448#comments</comments>
		<pubDate>Wed, 23 Dec 2009 01:01:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[NEOG]]></category>
		<category><![CDATA[Neogen Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23448</guid>
		<description><![CDATA[Neogen Corp. (NEOG) recently posted fiscal second quarter results. The company’s GAAP net income grew 18% to $4.6 million, compared to $3.9 million in the year-ago period. Adjusting for a 3-for-2 stock split effective Dec 15, earnings per share came in at 20 cents per share, which edged past the Zacks Consensus Estimate by a penny. Neogen develops and markets products dedicated to food and animal safety. The company&#8217;s Food Safety division markets dehydrated culture media, and diagnostic test kits to detect food borne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen&#8217;s Animal Safety division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides. During the quarter, Neogen completed the acquisition of BioKits food safety business of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/22/neog-neogen-beats-earnings-expectations-by-a-penny/23448/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GPRO) Gen-Probe Earns U.S. Food and Drug Administration Approval</title>
		<link>http://www.stockbloghub.com/2009/11/25/gpro-gen-probe-earns-u-s-food-and-drug-administration-approval/21307</link>
		<comments>http://www.stockbloghub.com/2009/11/25/gpro-gen-probe-earns-u-s-food-and-drug-administration-approval/21307#comments</comments>
		<pubDate>Wed, 25 Nov 2009 18:14:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21307</guid>
		<description><![CDATA[Recently, Gen-Probe Inc. (GPRO) announced that it has received the green light from the U.S. Food and Drug Administration (FDA) to market ProParaflu Plus assay. The assay, developed by Prodesse, a wholly-owned subsidiary of Gen-Probe, is a molecular test for detecting and differentiating parainfluenza 1, 2, and 3 viruses that cause lower respiratory tract infections. The assay makes use of real-time polymerase chain reaction to identify parainfluenza 1, 2, and 3 viruses from nasal swabs. Since it utilizes the same internal control as Prodesse&#8217;s other tests for respiratory infectious diseases, a single nucleic acid extract can be tested with any combination of its other products which have received FDA clearance &#8211; ProFlu Plus, Pro hMPV Plus and ProFlu-ST. As a reminder, ProFlu Plus received FDA approval in 2008 for detecting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/25/gpro-gen-probe-earns-u-s-food-and-drug-administration-approval/21307/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GPRO) Millipore &amp; Roka to Collaborate</title>
		<link>http://www.stockbloghub.com/2009/09/16/gpro-millipore-roka-to-collaborate/15376</link>
		<comments>http://www.stockbloghub.com/2009/09/16/gpro-millipore-roka-to-collaborate/15376#comments</comments>
		<pubDate>Wed, 16 Sep 2009 22:27:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[GPRO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15376</guid>
		<description><![CDATA[On Monday, Millipore Corp. (MIL) announced its collaboration with Roka Bioscience Inc. to develop molecular assays and portable instruments for biopharmaceutical production. Roka Bioscience is a new, independent company created following the spin-off of the industrial testing business of Gen-Probe Inc. (GPRO). After the spin-off, Gen-Probe transferred its partnership agreements with Millipore and GE Water (a business unit of CT-based General Electric (GE). Roka Bioscience is now engaged in developing real-time molecular tests for biopharmaceutical, food, and water safety testing. Gen-Probe initially plans to own 19.9% of the new company. Affiliates of three private equity firms, OrbiMed Advisors, TPG Biotechnology and New Enterprise Associates have agreed to provide $37.2 million to complete the development of several industrial-scale molecular assays. Gen-Probe contributed industrial assets that include its closed unit dose assay ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/gpro-millipore-roka-to-collaborate/15376/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

